Results 221 to 230 of about 321,714 (246)

Colorectal cancer—Is there an alternative to 5-FU?

European Journal of Cancer, 1997
info:eu-repo/semantics ...
openaire   +3 more sources

Acute Encephalopathy Attributed to 5‐FU

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996
Acute encephalopathy attributable to 5‐fluorouracil (5‐FU) is rare. A patient experienced this reaction associated with a continuous 5‐FU infusion. The etiology of the event remains uncertain, but it is generally reversible and does not preclude retreatment with 5‐FU at reduced dosages. Steroids and thiamine may expedite neurologic recovery.
C J, Langer, A, Hageboutros, D D, Kloth, D, Roby, A H, Shaer   +4 more
openaire   +2 more sources

Efficacy of adjuvant chemotherapy with 5-Fu/leucovorin and 5-Fu/levamisole in colon cancer

Gastroenterology, 1998
Previous studies have demonstrated the positive impact of adjuvant chemotherapy with 5-FU/levamisole on survival of patients with stage I11 colon cancer. In metastatic cancer, biochemical modulation of 5-FU leads to increased remission rates. Therefore, the effects of 5-FU/leucovorin (450 and 100 mg/m 2 i,v.
R. Porschen, A. Bermann, T. Löffler, G. Haack, K. Rettig, Y. Anger, G. Strohmeyer   +6 more
openaire   +1 more source

Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rats

Anti-Cancer Drugs, 1997
A new formulation has been developed for the delivery of 5-fluorouracil (5-FU) in treating peritoneal carcinomatosis. The new formulation (5-FU-MS) involves the incorporation of 5-FU into microspheres composed of a poly(glycolide-co-lactide) matrix. The incorporated 5-FU is released slowly over a 3 week period. We investigated the drug distribution and
A, Hagiwara, C, Sakakura, H, Tsujimoto, T, Imanishi, M, Ohgaki, J, Yamasaki, K, Sawai, T, Takahashi, T, Fujita, A, Yamamoto, S, Muranishi, Y, Ikada   +11 more
openaire   +2 more sources

Intraoperative Treatment with 5-FU

2018
The use of 5-FU and its effectiveness in the treatment of keloid and hypertrophic scar have been evidenced in several studies reaching very favorable results. Currently, the use has been directed as therapy on healing states with poor evolution already established, where the inhibitory effect of 5-FU on fibroblastic proliferation results in the ...
Guillermo Blugerman, Diego Schavelzon, Roberto Rodrigo Cáceres, Victoria Schavelzon, Miguel Mussi, Guido Blugerman   +5 more
openaire   +1 more source

Successful treatment with 5-Fu

Ophthalmology, 2003
Barry A, Schechter, Robert S, Nagler
openaire   +2 more sources

The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.

Digestive diseases and sciences, 2013
Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients.To investigate whether nuclear factor erythroid 2-related factor 2 (Nrf2) was associated with drug resistance in 5-FU resistant Bel-7402 (Bel-7402/5-FU) cells, and if sorafenib, an oral multikinase inhibitor targeting the ...
Suna, Zhou, Wenguang, Ye, Xiaoyi, Duan, Mingxin, Zhang, Jiansheng, Wang   +4 more
openaire   +1 more source

[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].

Gan to kagaku ryoho. Cancer & chemotherapy, 1987
An evaluation was made, using in vivo subrenal capsule (SRC) assay, of the chemosensitivity of 12 human neoplastic tissues including 7 gastric cancers, 2 colo-rectal cancers, 2 lung cancers and 1 breast cancer, exposed to 5-fluorouracil (5-FU) and the 5-FU derivatives: tegafur (FT), UFT and hexylcarbamoyl-5-FU (HCFU).
H, Anai, Y, Maehara, H, Kusumoto, H, Masuda, K, Sugimachi   +4 more
openaire   +1 more source

[Comparative clinical study on 5-FU concentrations for oral HCFU and i.v. 5-FU].

Gan to kagaku ryoho. Cancer & chemotherapy, 2000
Using the cross-over method, the same patients were administered continuous intravenous injections of 5-FU and HCFU, an oral derivative of 5-FU widely used for breast and colon cancer in Japan. The pharmacokinetics of 5-FU in blood of both drugs were then compared.
M, Miyauchi, N, Yamamoto, M, Matsumoto, T, Shishikura, K, Hyakutake   +4 more
openaire   +1 more source

[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].

Gan to kagaku ryoho. Cancer & chemotherapy, 2003
5-FU hepato-arterial infusion (HAI) is powerful chemotherapy for liver metastases of colorectal cancers. Event though hepatic lesions are controlled by 5-FU HAI, we have found that extra-hepatic lesions are the limiting factor for colorectal cancer patients. General chemotherapy is necessary in addition to 5-FU HAI.
Michio, Maruyama, Masakazu, Ebuchi, Takeshi, Nagahama, Itaru, Takashima, Kumi, Hasegawa, Takanori, Ochiai, Shinsuke, Natui   +6 more
openaire   +1 more source